The weak EPS won’t be praised by investors imo. Recell Go won’t be a catalyst until it gets that FDA stamp of approval. New data for FDA doesn’t ensure victory; approval does. But the company still needs to execute to obtain profitability by some time in 2025. —Still paying back a high SOFR-rate loan in the meantime.
The weak EPS won’t be praised by investors imo. Recell Go won’t...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.62 |
Change
-0.150(5.42%) |
Mkt cap ! $157.7M | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.66 | $2.58 | $1.612M | 614.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 13249 | $2.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.66 | 3448 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.62 |
Change
-0.150 ( 6.19 %) |
||||
| Open | High | Low | Volume | ||
| $2.61 | $2.65 | $2.61 | 10832 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| AVH (ASX) Chart |